DUBLIN–(BUSINESS WIRE)–The “Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast -2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.
The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
The diagnosis of Acute Respiratory Distress Syndrome (ARDS) is based on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests.
ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.
Acute Respiratory Distress Syndrome (ARDS) Treatment
The Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, was described as a form of respiratory failure that closely resembled respiratory distress syndrome in infants. This can be caused by a variety of pulmonary (such as pneumonia, aspiration) or non-pulmonary (like sepsis, pancreatitis, and trauma) abuses, leading to the development of non-hydrostatic pulmonary edema. The treatment of ARDS involves general supportive measures, ventilator strategies, and appropriate treatment of the underlying condition. Besides general supportive measures, pharmacological interventions are commonly considered throughout ARDS. Although research involving the investigation of drug candidates is being carried out for over a decade, only a few pharmacological therapies have emerged for ARDS. (Read more…)
Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. Other treatment options, which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.
Acute Respiratory Distress Syndrome (ARDS) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of ARDS, Severity-specific Incidence of ARDS, and Incidence of ARDS by Risk Factors scenario of Acute Respiratory Distress Syndrome (ARDS) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Key Findings
- In the 7MM, the total incident population of ARDS is estimated to be 799,872, in 2017.
- Generally, the highest number of incident cases were assessed for ARDS due to Pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS.
- Due to occurrence of COVID-19, there is a sudden increase in the cases of ARDS in the US, from 495,655 in 2
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS).
- To understand the future market competition in the ARDS market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) market.
- To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market.
List of Companies
- Faron Pharmaceuticals
- PhaseBio Pharmaceuticals
- Sage Therapeutics
- Chimerix
- Direct Biologics
- Kiniksa Pharmaceuticals
- Pluristem Therapeutics
- Alexion Pharmaceuticals
- Biomarck Pharmaceuticals
- Athersys
- Veru
- Apeptico Forschung und Entwicklung GmbH
- Alexion Pharmaceuticals
- Humanigen, Inc.
- Roche Pharma AG
- Alexion
- Mylan Laboratories
- Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
- Laboratoire francais de Fractionnement et de Biotechnologies
- Ache Laboratorios Farmaceuticos
- Implicit Bioscience
- Alexion
- NeuroRx/Relief Therapeutics
- CytoDyn
- Kiniksa
- Biohaven Pharmaceutical Holding Co. Ltd.
- Kinevant Sciences GmbH/Roivant Sciences
- Iltoo Pharma
- Eli Lilly and Company
- Merck/Eli Lilly
- Apeiron Biologics
- Roche AG
- And Many More Companies!
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pin6wx
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900